Header Logo

Connection

Renate Strehlau to Male

This is a "connection" page, showing publications Renate Strehlau has written about Male.
Connection Strength

1,159
  1. HIV diagnostic challenges in breast-fed infants of mothers on antiretroviral therapy. AIDS. 2019 09 01; 33(11):1751-1756.
    View in: PubMed
    Score: 0,073
  2. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa. J Pediatric Infect Dis Soc. 2018 Aug 17; 7(3):e70-e77.
    View in: PubMed
    Score: 0,068
  3. Neurodevelopmental assessment of HIV-exposed uninfected and early-treated HIV-infected children: study protocol. BMC Res Notes. 2018 Apr 06; 11(1):235.
    View in: PubMed
    Score: 0,066
  4. HIV-associated neurodevelopmental delay: prevalence, predictors and persistence in relation to antiretroviral therapy initiation and viral suppression. Child Care Health Dev. 2016 11; 42(6):881-889.
    View in: PubMed
    Score: 0,059
  5. Developmental status of preschool children receiving cART: a descriptive cohort study. Child Care Health Dev. 2016 May; 42(3):410-4.
    View in: PubMed
    Score: 0,057
  6. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged =3 months to <6 years. J Int AIDS Soc. 2015; 18:19467.
    View in: PubMed
    Score: 0,055
  7. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Aug 01; 60(4):369-76.
    View in: PubMed
    Score: 0,045
  8. Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. J Int AIDS Soc. 2025 Feb; 28(2):e26414.
    View in: PubMed
    Score: 0,027
  9. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study. Lancet HIV. 2024 May; 11(5):e300-e308.
    View in: PubMed
    Score: 0,025
  10. Growth Trajectories Over the First Year of Life Among Early-Treated Infants with Human Immunodeficiency Virus and Infants Who are Human Immunodeficiency Virus-Exposed Uninfected. J Pediatr. 2024 Jul; 270:114018.
    View in: PubMed
    Score: 0,025
  11. Higher CCR5 density on CD4 + T-cells in mothers and infants is associated with increased risk of in-utero HIV-1 transmission. AIDS. 2024 06 01; 38(7):945-954.
    View in: PubMed
    Score: 0,025
  12. Microbiota in the oral cavity of school-age children with HIV who started antiretroviral therapy at young ages in South Africa. AIDS. 2023 08 01; 37(10):1583-1591.
    View in: PubMed
    Score: 0,024
  13. Active Intrapartum SARS-CoV-2 Infection and Pregnancy Outcomes. Am J Perinatol. 2022 12; 39(S 01):S42-S48.
    View in: PubMed
    Score: 0,023
  14. An HIV Vaccine Protective Allele in FCGR2C Associates With Increased Odds of Perinatal HIV Acquisition. Front Immunol. 2021; 12:760571.
    View in: PubMed
    Score: 0,021
  15. Switch to Efavirenz Attenuates Lipoatrophy in Girls With Perinatal HIV. J Pediatr Gastroenterol Nutr. 2021 01 01; 72(1):e15-e20.
    View in: PubMed
    Score: 0,020
  16. Quantifying the Dynamics of HIV Decline in Perinatally Infected Neonates on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2020 10 01; 85(2):209-218.
    View in: PubMed
    Score: 0,020
  17. Behavioral Functioning and Quality of Life in South African Children Living with HIV on Antiretroviral Therapy. J Pediatr. 2020 12; 227:308-313.e2.
    View in: PubMed
    Score: 0,019
  18. Deficits in Bone Architecture and Strength in Children Living With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2020 05 01; 84(1):101-106.
    View in: PubMed
    Score: 0,019
  19. Negative Diagnostic PCR Tests in School-Aged, HIV-Infected Children on Antiretroviral Therapy Since Early Life in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2020 04 01; 83(4):381-389.
    View in: PubMed
    Score: 0,019
  20. Bone Quality Measured Using Calcaneal Quantitative Ultrasonography Is Reduced Among Children with HIV in Johannesburg, South Africa. J Pediatr. 2019 12; 215:267-271.e2.
    View in: PubMed
    Score: 0,018
  21. Distinct epigenetic profiles in children with perinatally-acquired HIV on antiretroviral therapy. Sci Rep. 2019 07 19; 9(1):10495.
    View in: PubMed
    Score: 0,018
  22. Mitochondrial Impairment in Well-Suppressed Children with Perinatal HIV-Infection on Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2020 01; 36(1):27-38.
    View in: PubMed
    Score: 0,018
  23. Educational delays among children living with perinatally-acquired HIV in Johannesburg, South Africa. AIDS Care. 2020 04; 32(4):438-444.
    View in: PubMed
    Score: 0,018
  24. 12-month outcomes of HIV-infected infants identified at birth at one maternity site in Johannesburg, South Africa: an observational cohort study. Lancet HIV. 2018 12; 5(12):e706-e714.
    View in: PubMed
    Score: 0,017
  25. Biomarkers of Aging in HIV-Infected Children on Suppressive Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2018 08 15; 78(5):549-556.
    View in: PubMed
    Score: 0,017
  26. Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study. J Pediatric Infect Dis Soc. 2018 May 15; 7(2):143-150.
    View in: PubMed
    Score: 0,017
  27. Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children. PLoS One. 2018; 13(4):e0195514.
    View in: PubMed
    Score: 0,017
  28. Decreased bone turnover in HIV-infected children on antiretroviral therapy. Arch Osteoporos. 2018 Apr 05; 13(1):40.
    View in: PubMed
    Score: 0,017
  29. Dietary Inadequacies in HIV-infected and Uninfected School-aged Children in Johannesburg, South Africa. J Pediatr Gastroenterol Nutr. 2017 09; 65(3):332-337.
    View in: PubMed
    Score: 0,016
  30. Prevalence and outcomes of HIV-1 diagnostic challenges during universal birth testing - an urban South African observational cohort. J Int AIDS Soc. 2017 08 29; 20(Suppl 6):21761.
    View in: PubMed
    Score: 0,016
  31. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial. Clin Infect Dis. 2017 Aug 01; 65(3):477-485.
    View in: PubMed
    Score: 0,016
  32. Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants. AIDS. 2017 Jan 28; 31(3):355-364.
    View in: PubMed
    Score: 0,015
  33. Efavirenz is associated with higher bone mass in South African children with HIV. AIDS. 2016 10 23; 30(16):2459-2467.
    View in: PubMed
    Score: 0,015
  34. Unusually High Calcaneal Speed of Sound Measurements in Children with Small Foot Size. Ultrasound Med Biol. 2017 01; 43(1):357-361.
    View in: PubMed
    Score: 0,015
  35. Extent of disclosure: what perinatally HIV-infected children have been told about their own HIV status. AIDS Care. 2017 03; 29(3):378-386.
    View in: PubMed
    Score: 0,015
  36. Decreased Vigorous Physical Activity in School-Aged Children with Human Immunodeficiency Virus in Johannesburg, South Africa. J Pediatr. 2016 05; 172:103-9.
    View in: PubMed
    Score: 0,014
  37. Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. BMC Infect Dis. 2016 Feb 02; 16:56.
    View in: PubMed
    Score: 0,014
  38. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial. JAMA. 2015 Nov 03; 314(17):1808-17.
    View in: PubMed
    Score: 0,014
  39. Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed. AIDS. 2015 Jun 01; 29(9):1053-60.
    View in: PubMed
    Score: 0,014
  40. Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Virol Methods. 2014 Oct; 207:182-7.
    View in: PubMed
    Score: 0,013
  41. Timing of maternal HIV testing and uptake of prevention of mother-to-child transmission interventions among women and their infected infants in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):e170-8.
    View in: PubMed
    Score: 0,013
  42. Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther. 2014; 19(4):399-406.
    View in: PubMed
    Score: 0,012
  43. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. BMC Pediatr. 2014 Feb 12; 14:39.
    View in: PubMed
    Score: 0,012
  44. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. Pediatr Infect Dis J. 2013 Aug; 32(8):851-5.
    View in: PubMed
    Score: 0,012
  45. Adherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy. Pediatr Infect Dis J. 2013 May; 32(5):489-94.
    View in: PubMed
    Score: 0,012
  46. Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. J Pediatr. 2013 Jun; 162(6):1138-45, 1145.e1-2.
    View in: PubMed
    Score: 0,012
  47. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child. 2013 Apr; 98(4):258-64.
    View in: PubMed
    Score: 0,011
  48. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
    View in: PubMed
    Score: 0,011
  49. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
    View in: PubMed
    Score: 0,010
  50. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis. 2011 Feb 15; 52(4):514-21.
    View in: PubMed
    Score: 0,010
  51. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis. 2010 Apr 15; 201(8):1121-31.
    View in: PubMed
    Score: 0,010
  52. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 2009 Jun 01; 23(9):1097-107.
    View in: PubMed
    Score: 0,009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.